Dr. Faizan Malik

Hematology Oncology, University of Maryland Medical Center, Greenbaum comprehensive cancer center

Lung cancer, Lymphoma, Multiple myeloma

[Dr Rishabh Jain @DrRishabhOnco]

Practice-changing in colon cancer?

Adjuvant immunotherapy + chemo cuts recurrence risk by 50% in stage III dMMR colon cancer.

ATOMIC trial delivers.

👥 Study population
Resected stage III dMMR/MSI-H colon cancer
⚠️ ~54% high-risk (T4/N2)

⚔️ Arms
🟦 Atezolizumab + mFOLFOX6 → atezo maintenance (1 year total)
⬜ mFOLFOX6 alone (6 months)

📊 Key results
•3-year DFS: 86.3% vs 76.2%
•HR: 0.50 (P<0.001)
👉 ~10% absolute gain

⚠️ Toxicity trade-off
•Grade 3-4 AEs: 84% vs 72%
•More immune AEs (thyroid, colitis, hyperglycemia)

❗ OS immature

🎯 Clinical takeaway
For stage III dMMR colon cancer,
👉 IO + FOLFOX is likely the new adjuvant standard

🔬 Test MMR in ALL colon cancers. This now directly impacts adjuvant therapy.

📖 Full paper in comment ⬇️

#OncoTwitter #MedTwitter #ColorectalCancer #GIOnc @OncoAlert @myesmo @esmo_open @asco

[Karamvir Yadav @K_Yadavir]

The KRAS era has finally arrived in oncology.

Key insights from the evolving landscape of KRAS inhibitors:

• KRAS mutations drive ~20% of cancers
• KRASG12C inhibitors show strongest activity in NSCLC
• Combination strategies critical in CRC
• Resistance remains the major challenge
• Next-gen pan-KRAS & pan-RAS inhibitors in development

Clinical snapshot 👇
#kras #medtwitter #oncology @pashtoonkasi @DrRishabhOnco @ValenzaCarmine @dr_dirican @OncoAlert @oncodaily @dr_yakupergun @1min_IDconsult @NurseHann100 @CR_AACR @ASCOPost @todrashish

[Vincent Rajkumar @VincentRK]

Just in: Good news for the myeloma field.

FDA approves teclistamab plus daratumumab (Tec-Dara) combination for myeloma for patients who have had at least one prior line of therapy.
Note: Always use Tec-Dara with monthly IVIG. It’s not optional.

That was fast! And this is unprecedented curve is why.

[Vincent Rajkumar @VincentRK]

This changes how we approach first relapse.

In Dara sensitive patients: Tec-Dara or Cilta-cel are the top two choices.

If Dara refractory: Bispecifics alone or Cilta-cel are the main options.

CART and Bispecifics both need close monitoring and specialized care and certain requirements. So for some patients, we may still use triplets.

[MV Chandrakanth @ChandrakanthMv]

• Pegfilgrastim timing matters
• 24h → higher early WBC spike
• 72h → ↓ bone pain
• 72h → more controlled WBC curve
• No loss of efficacy
Maybe 72 hours is the sweet spot 👇
#MVOnco #Pegfilgrastim #GCSF #Oncology #SupportiveCare #DoseDense

[Daniel Peters @DPetersMD]

Amazing to be a leukemia MD in this day &amp; age. This is the timeline of new💊approvals in AML that I get to show our @MCG_AUG Heme/Onc fellows. The last decade has sure been exciting. What's next? #leusm #MedEd

[Elad Sharon @EladSharonMD]

Seriously, this is big…

[MV Chandrakanth @ChandrakanthMv]

🚀 #ASCOGU26 is almost here! What might the data show?
• Practice-changing perioperative IO?
• ctDNA precision?
🤖 Note: These are only AI predictions.
👀 Watch out for the final readouts!
#MedTwitter #GUOnc #MVOnco

[Toni Choueiri, MD @DrChoueiri]

ASCO GU 2026 – Top 15 Trials with Potential Practice Impact @ASCO #GU26

[Benlazar S M A @smbenlazar]

How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know https://t.co/PH1XNpp7S2 #mdpijcm via @JCM_MDPI #leusm

[MV Chandrakanth @ChandrakanthMv]

𝐏𝐅𝐒 ≠ 𝐃𝐨𝐑.
PFS asks: How long does treatment control disease — for 𝐞𝐯𝐞𝐫𝐲𝐨𝐧𝐞?
DoR asks: How long does the response last — for 𝐫𝐞𝐬𝐩𝐨𝐧𝐝𝐞𝐫𝐬 𝐨𝐧𝐥𝐲?
Same endpoint framework. 𝐕𝐞𝐫𝐲 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬. 🧠
#OncologyEducation #ClinicalTrials
#ExamPearls #MVOnco

[MV Chandrakanth @ChandrakanthMv]

𝐃𝐅𝐒, 𝐏𝐅𝐒, 𝐄𝐅𝐒 — 𝐬𝐚𝐦𝐞 𝐥𝐞𝐭𝐭𝐞𝐫𝐬. 𝐕𝐞𝐫𝐲 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬.

🔹 𝐃𝐅𝐒: Did the disease come back?
🔹 𝐏𝐅𝐒: Did the disease grow?
🔹 𝐄𝐅𝐒: Did anything go wrong?
Endpoints matter.
𝐂𝐨𝐧𝐭𝐞𝐱𝐭 𝐦𝐚𝐭𝐭𝐞𝐫𝐬 𝐦𝐨𝐫𝐞. 🧠

#Oncology #ClinicalTrials
#EvidenceBasedMedicine #MVOnco

[MV Chandrakanth @ChandrakanthMv]

𝐖𝐡𝐲 𝐥𝐞𝐮𝐜𝐨𝐯𝐨𝐫𝐢𝐧 𝐰𝐨𝐫𝐤𝐬 𝐰𝐢𝐭𝐡 𝟓-𝐅𝐔 𝐢𝐧 𝐆𝐈 𝐜𝐚𝐧𝐜𝐞𝐫𝐬—𝐛𝐮𝐭 𝐧𝐨𝐭 𝐢𝐧 𝐡𝐞𝐚𝐝 & 𝐧𝐞𝐜𝐤 𝐜𝐚𝐧𝐜𝐞����.
Not tradition. 𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦. 🧬
✔️ TS inhibition drives efficacy in GI tumors
❌ Not the dominant pathway in HNSCC

#Oncology #5FU #GIOncology #HNSCC
#EvidenceBasedMedicine #MVOnco

[MV Chandrakanth @ChandrakanthMv]

🧠📘 𝐖𝐡𝐞𝐭𝐡𝐞𝐫 𝐢𝐧 𝐞𝐱𝐚𝐦𝐬 𝐨𝐫 𝐢𝐧 𝐩𝐫𝐚𝐜𝐭𝐢𝐜𝐞, 𝐭𝐡𝐢𝐬 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧 𝐢𝐬 𝐮𝐧𝐚𝐯𝐨𝐢𝐝𝐚𝐛𝐥𝐞.
🧬 𝐅𝐎𝐋𝐅𝐎𝐗—𝐦𝐚𝐝𝐞 𝐬𝐢𝐦𝐩𝐥𝐞.

#FOLFOX #MedicalOncology
#OncologyEducation #MVOnco

[Oncology Brothers @OncBrothers]

2025 approvals: Summary of 7 new drugs/indications in GI malignancies by @FDAOncology

1. #Sotorasib
2. #Pembrolizumab
3. #Cabozantinib in NET
4. #Ipilimumab &amp; #Nivolumab x2
5. #Retifanlimab in Anal Ca
6. #Durvalumab GEJ/Gastric Ca

#gism #OncTwitter #MedTwitter

[Dr Rishabh Jain @DrRishabhOnco]

The Paclitaxel + Carboplatin "CarboTaxol" doublet is the bread and butter of oncology for a reason. 🍞🧈

But why does this specific combo work so well?
It’s all about the "Freeze and Snap" synergy. ❄️💥

1️⃣ The Freezer (Paclitaxel):
Paclitaxel stabilizes microtubules, preventing depolymerization.
It freezes the cell’s skeleton in the M-phase (Mitosis). The cell tries to divide but gets stuck. 🛑 

2️⃣ The Snap (Carboplatin):
While the cell is arrested and stressed, Carboplatin slides in.
It acts as an alkylating agent, forming reactive platinum complexes that bind to DNA (cross-linking). 🧬🔗 

🤝 The Synergy (Why 1+1 = 3):
The magic lies in the timing.
Paclitaxel arrests cells in the G2/M phase.
Cells in this phase are less efficient at repairing the DNA damage caused by Carboplatin.
The "Freeze" prevents the "Repair," leading to accumulation of DNA damage ➡️ Apoptosis (Cell Death). ☠️ 

💡 Clinical Pearl (The Sequence Matters):
This is why we often administer Taxane before Platinum.
Giving Paclitaxel first avoids the antagonistic effect where Carboplatin might inhibit the uptake or cytotoxicity of the taxane.
It also reduces thrombocytopenia! 📉🩸

#Oncology #MedTwitter #OncTwitter
@OncoAlert @myesmo @esmo_open @asco

[Benlazar S M A @smbenlazar]

Risk adapted approach to Burkitt lymphoma #ASH25

[Benlazar S M A @smbenlazar]

CML recommendations ELN&amp;NCCN 2025 #ASH25

[Oncology Brothers @OncBrothers]

2024 approvals: Summary of 14 new drugs/indications in #LungCancer by @US_FDA

1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab
9. #Ensartinib

#lcsm #OncTwitter #MedTwitter

[Oncology Brothers @OncBrothers]

2025 approvals: Summary of 9 new drugs/indications in #LungCancer by @US_FDA

1. #TelisoV
2. #Taletrectinib
3. #DatoDXd
4. #Sunvozertinib
5. #Zongertinib
6. #Lurbinectedin (w/Atezo)
7. #Sevabertinib
8. #Tarlatamab
9. SubQ #Amivantamab

#lcsm #OncTwitter #MedTwitter